Overview

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well E7389 works in treating patients with metastatic or recurrent head and neck cancer.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)